Biocryst Pharmaceuticals Stock In The News
| BCRX Stock | USD 4.16 0.05 1.19% |
The overall news coverage of BioCryst Pharmaceuticals from major news outlets shows bullish sentiment on 6 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of BioCryst Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards BioCryst Pharmaceuticals. The specific impact of BioCryst Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of BioCryst Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using BioCryst Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out BioCryst Pharmaceuticals Backtesting and BioCryst Pharmaceuticals Hype Analysis. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
BioCryst |
BioCryst Pharmaceuticals Today Top News and Investor Outlook
BioCryst Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide BioCryst and other traded companies coverage. We help investors stay connected with BioCryst headlines for the 28th of April to make an informed investment decision based on correlating the impacts of news items on BioCryst Stock performance. Please note that trading solely based on the BioCryst Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.BioCryst Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the BioCryst earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.
BioCryst Largest EPS Surprises
Earnings surprises can significantly impact BioCryst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-08-07 | 2017-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2013-02-19 | 2012-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2004-02-04 | 2003-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2000-10-25 | 2000-09-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2000-02-02 | 1999-12-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2013-11-05 | 2013-09-30 | -0.11 | -0.14 | -0.03 | 27 |
BioCryst Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to BioCryst Pharmaceuticals Stock. Current markets are strongly bullish. About 73% of major world exchanges and indexes are currently up. See today's market update for more information.
22nd of April 2024
With 80 percent ownership, BioCryst Pharmaceuticals, Inc. boasts of strong institutional b... at finance.yahoo.com
17th of April 2024
BioCryst Announces Approval of ORLADEYO by the Brazilian Health Regulatory Agency at benzinga.com
16th of April 2024
Pint Pharma anuncia a aprovao de ORLADEYO , primeira terapia oral, indicada como preveno d... at businesswire.com
11th of April 2024
BioCryst Pharmaceuticals Receives Buy Rating from Needham Company LLC - Defense World at news.google.com
3rd of April 2024
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 at finance.yahoo.com
13th of March 2024
Clearside Biomedical, Inc. Q4 2023 Earnings Call Transcript at finance.yahoo.com
27th of February 2024
BioCryst Pharmaceuticals, Inc. Shares Sold by Profund Advisors LLC at thelincolnianonline.com
16th of February 2024
BioCryst Pharmaceuticals, Inc. Shares Sold by E Fund Management Co. Ltd. at thelincolnianonline.com
BioCryst Pharmaceuticals Investors Sentiment
The influence of BioCryst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioCryst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioCryst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.
Check out BioCryst Pharmaceuticals Backtesting and BioCryst Pharmaceuticals Hype Analysis. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.